Inventory (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of current inventory | Inventory consists of the following (in thousands):
The Company identified approximately $0.5 million in unsalable product which is included in prepaid expenses and other current assets in the condensed consolidated balance sheet at March 31, 2026 as the Company believes it will be reimbursed. The Company's inventory write-downs were approximately $0.5 million during the three months ended March 31, 2026, and was recorded within cost of sales in the condensed consolidated statements of operations and relates to slow-moving FYCOMPA® inventory and unsalable AGAMREE® inventory. There were no inventory reserves during the three months ended March 31, 2025. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||